Azelaic acid

Drug Profile

Azelaic acid

Alternative Names: BAY39-6251; Finacea; Finacea Foam; Skinoren Gel

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer Dermatology; Bayer HealthCare Pharmaceuticals Inc.
  • Class Antiacnes; Antibacterials; Dicarboxylic acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Melanosis; Rosacea
  • Discontinued Dermatitis

Most Recent Events

  • 28 Feb 2018 Bayer and Foamix initiate joint litigation against Teva and Perrigo, respectively, over ANDA submission in USA
  • 26 Oct 2015 Launched for Rosacea in USA (Topical, Foam)
  • 31 Jul 2015 Adverse events and efficacy data from pivotal phase-III trials in Rosacea (Topical, foam formulation) released by Bayer HealthCare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top